Description: Sernova Corp. is a clinical stage regenerative medicine company developing cell therapy based medical technologies for the treatment of chronic debilitating diseases such as diabetes, blood disorders including hemophilia and other diseases all of which are treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch(TM), a scalable, implantable medical device which forms a vascularized organ-like environment for the transplantation of its locally immune-protected therapeutic cells (self-cells, donor cells, ethically sourced stem cell derived therapeutic cells or xenogeneic cells) which then release proteins and/or hormones as required by the body. The objective of the company's products is to disrupt the standard of care treatments for these serious diseases to improve efficacy, significantly improve patient quality of life and to decrease the severe debilitating disease effects that progress with the standard of care treatments. The product to treat diabetes involves implantation of a small biocompatible medical device under the skin into which are placed immune protected cells which connect to the blood vessel supply to read blood sugar levels and release insulin accordingly, replacing the metabolic function of the pancreas. For hemophelia the cells would release the required protein, Factor VIII on a constant basis reducing or eliminating the need for frequent infusions of Factor VIII.
Home Page: www.sernova.com
The Stiller Centre
London,
ON
N6G 4X8
Canada
Phone:
519 858 5184
Officers
| Name | Title |
|---|---|
| Mr. Frank A. Holler MBA | Exec. Chairman |
| Dr. Philip M. Toleikis B.A., M.Sc., Ph.D. | Pres, CEO & Director |
| Mr. David Swetlow C.A, C.A., CPA | Chief Financial Officer |
| Mr. Douglas Maret | Chief Science Officer |
| Mr. Christopher Barnes | VP of Investor Relations |
Exchange: OTCQB
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.6904 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 1999-04-12 |
| Fiscal Year End: | October |
| Full Time Employees: | 0 |